Abstract: Drug delivery devices comprising a non-bioabsorbable polymer structure configured to support a composition comprising an active agent. The devices include a plurality of portions fused together and a recess configured to support the composition. At least one of the portions includes an impermeable polymer and at least one other portion includes a rate-limiting water-permeable polymer. The rate-limiting water-permeable polymer allows for transportation of the active agent to an exterior of the device.

Abstract: Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.

Abstract: Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.

Abstract: The present disclosure provides an ophthalmic composition comprising 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or its pharmaceutically acceptable salts; about 0.01% weight/volume to about 1.0% weight/volume of a buffer; and about 0.01% weight/volume to about 10% weight/volume of a tonicity agent.

Abstract: Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.

Abstract: Drug delivery devices comprising a non-bioabsorbable polymer structure configured to support a composition comprising an active agent. The devices include a plurality of portions fused together and a recess configured to support the composition. At least one of the portions includes an impermeable polymer and at least one other portion includes a rate-limiting water-permeable polymer. The rate-limiting water-permeable polymer allows for transportation of the active agent to an exterior of the device.

Abstract: Described herein are compounds and compositions for treating glaucoma and/or reducing introcular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.

Abstract: An additive manufacturing method is provided. A plurality of powder layers is stacked on a supporting plate in sequence. Energy beams are provided to the powder layers in sequence by using an energy source, such that each of the powder layers is at least partially shaped. The powder layers are heated by using a temperature control device, so as to control a temperature of each of the powder layers being shaped.

Abstract: An additive manufacturing apparatus including a supporting plate, an energy source and a temperature control device is provided. A plurality of powder layers are adapted to be stacked on the supporting plate in sequence. The energy source is adapted to provide energy beams to the powder layers in sequence, such that each of the powder layers is at least partially shaped. The temperature control device is adapted to heat the power layers, so as to control a temperature of each of the powder layers being shaped.

Abstract: Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.

Abstract: Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.

Abstract: Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.

Abstract: Drug delivery devices comprising a non-bioabsorbable polymer structure configured to support a composition comprising an active agent. The devices include a plurality of portions fused together and a recess configured to support the composition. At least one of the portions includes an impermeable polymer and at least one other portion includes a rate-limiting water-permeable polymer. The rate-limiting water-permeable polymer allows for transportation of the active agent to an exterior of the device.

Abstract: A method for treating a virus infection in a subject is provided. The method comprising administering to the subject in need an effective amount of a derivative of aniline selected from the group consisting of a compound of formula (I), a pharmaceutically acceptable salt of the compound of formula (I), a pharmaceutically acceptable ester of the compound of formula (I), and combinations thereof: wherein, R1 is C1 to C10 alkyl; R2 is H or C1 to C4 alkyl; and R3, R4, R5, R6 and R7 are independently H, —OH, halogen, C1 to C10 alkyl, C1 to C10 alkoxyl, or (C1 to C10 alkylene)-O—O—(C1 to C10 alkyl).

Abstract: A combined LED bulb comprises a base body, a light source module detachably arranged at one end of the base body, a light-transmitting hood body detachably covering the same ends of both the base body and the light source module, and a connector detachably connected to the other end of the base body. Through modular design of the elements, the purpose of reducing element, decreasing procedures, improving capacity and yield of finished lamps, and lowering manufacturing cost and labor cost is realized; and the combined light-emitting diode bulb is applicable to a manual production line and an automatic production line at the same time.

Abstract: A light emitting diode lamp tube includes a tubular body, a light source module and two latch cover. The tubular body includes two openings formed on two opposite ends of the tubular body respectively and two first joining portions disposed near the openings respectively. The light source module is inserted into the tubular body and includes a control circuit board, at least one terminal member and a plurality of light emitting diodes, wherein the light emitting diodes are coupled to the control circuit board, and the terminal member is coupled to one end of the control circuit board. The latch covers covering the opposite ends respectively, wherein each of the latch covers comprises a second joining portion joined to the first joining portion, at least one second positioning portion joined to the first positioning portion and two conductive pins electrically connected to the terminal member.

Abstract: A method for treating a virus infection in a subject is provided. The method comprising administering to the subject in need an effective amount of a derivative of aniline selected from the group consisting of a compound of formula (I), a pharmaceutically acceptable salt of the compound of formula (I), a pharmaceutically acceptable ester of the compound of formula (I), and combinations thereof: wherein, R1 is C1 to C10 alkyl; R2 is H or C1 to C4 alkyl; and R3, R4, R5, R6 and R7 are independently H, —OH, halogen, C1 to C10 alkyl, C1 to C10 alkoxyl, or (C1 to C10 alkylene)-O—O—(C1 to C10 alkyl).

Abstract: Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.

Abstract: Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.

Abstract: An endoscope controlling device includes a rigid tube mounted to an end face of a base and in communication with a compartment in the base. A positioning groove is formed in an inner periphery of the base and includes a bottom wall having a slot. A linear displacement control module includes a control member and a movable board. The control member is aligned with a through-hole in a periphery of the base. The control member controls longitudinal movement of the movable board in the compartment along a longitudinal axis of the base via a driving gear. An optical element receiving drum is mounted to the movable board. A rotational movement control module is mounted around the optical element receiving drum and received in the positioning groove of the base. A portion of the rotational movement control module is extended through the slot and exposed outside of the base.